National Institutes of Health: Diabetes Mellitus, Type 1 trials

The registry lists 71 Diabetes Mellitus, Type 1 studies with National Institutes of Health as lead sponsor. 4 are open to participants now and 21 have results posted.

Early Phase 1 1Phase 1 9Phase 2 40Phase 3 4No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs PlaceboNot yet recruitingNCT07683026Phase 2
• Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATGRecruitingNCT07216391Phase 2
• Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes MellitusRecruitingNCT07142252Phase 2
• Type 1 Diabetes Extension StudyRecruitingNCT02734277
• Siplizumab in T1DMTerminatedNCT05574335Phase 1/2Results posted
• STOP-T1D Low-Dose (ATG)TerminatedNCT04291703Phase 2Results posted
• A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041CompletedNCT04279613Phase 1Results posted
• Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes MellitusTerminatedNCT03428945Phase 2Results posted
• Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)CompletedNCT02580877Phase 2Results posted
• Tocilizumab (TCZ) in New-onset Type 1 DiabetesCompletedNCT02293837Phase 2Results posted
• ATG-GCSF in New Onset Type 1 DiabetesCompletedNCT02215200Phase 2Results posted
• CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1CompletedNCT01773707Phase 2Results posted
• A Research Trial of Aralast in New Onset Diabetes (RETAIN)TerminatedNCT01183468Phase 1Results posted
• Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"CompletedNCT01030861Phase 2Results posted
• Inducing Remission in Type 1 Diabetes With AlefaceptTerminatedNCT00965458Phase 2Results posted
• Canakinumab Study in Individuals With Newly Diagnosed Type 1 DiabetesCompletedNCT00947427Phase 2Results posted
• Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 DiabetesTerminatedNCT00837759Phase 2Results posted
• Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset SubjectsCompletedNCT00529399Phase 2Results posted
• Study of Antithymocyte Globulin for Treatment of New-onset T1DMTerminatedNCT00515099Phase 2Results posted
• Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes MellitusCompletedNCT00505375Phase 2Results posted
• Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes MellitusCompletedNCT00419562Phase 3Results posted
• Rituximab in New Onset Type 1 DiabetesCompletedNCT00279305Phase 2Results posted
• Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 DiabetesCompletedNCT00129259Phase 2Results posted
• New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical TrialCompletedNCT00100178Phase 2Results posted
• Islet Transplantation for Type 1 DiabetesCompletedNCT00014911Phase 2Results posted
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• Anti-TNFα to Delay or Prevent Progression to Stage 3 T1DWithdrawnNCT04729296Phase 2
• Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesActive, not recruitingNCT03929601Phase 2
• Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 DiabetesWithdrawnNCT03396484Phase 2
• 11C-5-HTP PET in Clinical Islet TransplantationCompletedNCT02689479Not applicable
• T and B Cell Responses in Autoimmune DiseasesTerminatedNCT01947036
• Extended Follow-Up After Islet Transplantation in T1DCompletedNCT01369082
• Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)No longer availableNCT01309022
• A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part IIWithdrawnNCT01183455Phase 2
• B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft FailureNo longer availableNCT01049633
• Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)CompletedNCT00999375Phase 2
• Natural History of Autoimmune Diabetes and Its ComplicationsTerminatedNCT00896610
• Adolescent Self-Management of Type 1 Diabetes: an Intervention (Completed)CompletedNCT00848705Early Phase 1
• Parental Management of Young Children's DiabetesCompletedNCT00847327Not applicable
• Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy IndividualsCompletedNCT00813228Phase 1
• Treatment With hOKT3gamma1(Ala-Ala) in T1DMTerminatedNCT00806572Phase 2
• Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney TransplantWithdrawnNCT00790439Phase 2
• Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet TransplantationCompletedNCT00789308Phase 2
• Assessment of Beta Cell Mass by PET Scans With [11C] Dihydrotetrabenazine (DTBZ) in Longstanding Type 1 Diabetes.CompletedNCT00738907
• Proleukin and Rapamune in Type 1 DiabetesCompletedNCT00525889Phase 1
• B-Lymphocyte Immunotherapy in Islet TransplantationTerminatedNCT00468442Phase 2
• LEA29Y (Belatacept) Emory Edmonton ProtocolCompletedNCT00468403Phase 2
• Efficacy of Islet After Kidney TransplantationCompletedNCT00468117Phase 3
• Strategies to Improve Islet SurvivalCompletedNCT00464555Phase 2
• Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 DiabetesCompletedNCT00434850Phase 2
• Islet Transplantation in Type 1 DiabetesCompletedNCT00434811Phase 3
• Diabetes Control and Complications Trial (DCCT)CompletedNCT00360815Not applicable
• Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET ScanCompletedNCT00351650
• Management of Type 1 Diabetes Among AdolescentsCompletedNCT00340639
• Nutritional Intervention to Prevent DiabetesCompletedNCT00333554Not applicable
• TEDDY - The Environmental Determinants of Diabetes in the YoungCompletedNCT00279318
• Family Management of Type 1 Diabetes in ChildrenCompletedNCT00273286Phase 2
• T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes MellitusCompletedNCT00212329
• Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical TrialsCompletedNCT00105352Not applicable
• Islet Transplantation for Patients With Type 1 DiabetesCompletedNCT00073281Phase 1
• Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)CompletedNCT00073255Phase 1
• Evaluation of a Diabetes Vaccine in Newly Diagnosed DiabeticsCompletedNCT00057499Phase 1
• Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free RegimenCompletedNCT00021801Phase 2
• Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free ImmunosuppressionCompletedNCT00021788Phase 2
• hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft FailureStatus unknownNCT00008801Phase 1/2
• Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing ImmunosuppressionCompletedNCT00006505Phase 2
• African-American Diabetes Intervention ProjectCompletedNCT00006160Not applicable
• Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes MellitusStatus unknownNCT00005665Phase 2
• Depression In Juvenile DiabeticsCompletedNCT00005116Not applicable
• The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)CompletedNCT00004984Phase 3
• Genetic Influence on Susceptibility to Type 1 Diabetes MellitusCompletedNCT00001985